Market Closed -
Oslo Bors
10:45:00 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
0.218
NOK
|
+2.83%
|
|
-0.91%
|
-93.27%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
100.3
|
237.2
|
611.7
|
564.7
|
241
|
Enterprise Value (EV)
1 |
99.08
|
161.2
|
576.9
|
507.7
|
234.1
|
P/E ratio
|
-6.58
x
|
-14.5
x
|
-15.6
x
|
-8.86
x
|
-3.39
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
23.2
x
|
57.9
x
|
62.2
x
|
71.5
x
|
33.9
x
|
EV / Revenue
|
22.9
x
|
39.3
x
|
58.6
x
|
64.3
x
|
32.9
x
|
EV / EBITDA
|
-6.13
x
|
-7.99
x
|
-11.9
x
|
-6.17
x
|
-2.69
x
|
EV / FCF
|
-10.2
x
|
-30.2
x
|
-11.4
x
|
-11.3
x
|
-4.23
x
|
FCF Yield
|
-9.81%
|
-3.32%
|
-8.77%
|
-8.81%
|
-23.7%
|
Price to Book
|
5.9
x
|
2.74
x
|
7.65
x
|
5.28
x
|
6.22
x
|
Nbr of stocks (in thousands)
|
4,459
|
7,751
|
8,739
|
10,083
|
10,343
|
Reference price
2 |
22.50
|
30.60
|
70.00
|
56.00
|
23.30
|
Announcement Date
|
5/31/19
|
6/18/20
|
4/6/21
|
5/4/22
|
6/14/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
0.001
|
4.323
|
4.099
|
9.839
|
7.901
|
7.114
|
EBITDA
1 |
-12.2
|
-16.17
|
-20.17
|
-48.66
|
-82.32
|
-87.15
|
EBIT
1 |
-13.17
|
-17.29
|
-21.87
|
-51.36
|
-86.1
|
-91.05
|
Operating Margin
|
-1,316,857.8%
|
-399.86%
|
-533.55%
|
-522.03%
|
-1,089.71%
|
-1,280.01%
|
Earnings before Tax (EBT)
1 |
-13.17
|
-17.46
|
-22.18
|
-49.71
|
-86.29
|
-93.7
|
Net income
1 |
-9.408
|
-12.93
|
-16.34
|
-37.41
|
-65.4
|
-71.14
|
Net margin
|
-940,826.6%
|
-299.06%
|
-398.54%
|
-380.17%
|
-827.74%
|
-1,000.07%
|
EPS
2 |
-3.781
|
-3.422
|
-2.108
|
-4.491
|
-6.324
|
-6.878
|
Free Cash Flow
1 |
-11.9
|
-9.725
|
-5.345
|
-50.62
|
-44.73
|
-55.4
|
FCF margin
|
-1,190,367.6%
|
-224.95%
|
-130.4%
|
-514.5%
|
-566.16%
|
-778.75%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/1/18
|
5/31/19
|
6/18/20
|
4/6/21
|
5/4/22
|
6/14/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
17.1
|
1.24
|
76
|
34.8
|
57
|
6.91
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-11.9
|
-9.72
|
-5.35
|
-50.6
|
-44.7
|
-55.4
|
ROE (net income / shareholders' equity)
|
-64.2%
|
-62.7%
|
-32.4%
|
-46%
|
-70.3%
|
-95.8%
|
ROA (Net income/ Total Assets)
|
-41.3%
|
-39.7%
|
-21.3%
|
-33.4%
|
-50%
|
-49.8%
|
Assets
1 |
22.8
|
32.57
|
76.7
|
112
|
130.9
|
142.9
|
Book Value Per Share
2 |
10.80
|
3.810
|
11.20
|
9.150
|
10.60
|
3.750
|
Cash Flow per Share
2 |
6.870
|
0.3300
|
9.800
|
4.180
|
5.510
|
0.6700
|
Capex
1 |
1.49
|
1.44
|
3.2
|
7.67
|
4.6
|
4.85
|
Capex / Sales
|
148,564.7%
|
33.4%
|
78.09%
|
77.94%
|
58.16%
|
68.24%
|
Announcement Date
|
6/1/18
|
5/31/19
|
6/18/20
|
4/6/21
|
5/4/22
|
6/14/23
|
|
1st Jan change
|
Capi.
|
---|
| -93.27% | 9.94M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|